CMS on Tuesday proposed making its new Medicare Part D 340B data repository mandatory for covered entities—nine months after finalizing [...] …
Blog Posts
Drug purchases under the 340B program reached a record $100 billion in 2025, marking a 23% increase over the $81.4 [...] …
Please Login or Become a Paid Subscriber to View this Content
A new potential 340B rebate pilot, drugmaker 340B in-house pharmacy claims data requirements and new congressional reform proposals dominated discussions [...] …
Please Login or Become a Paid Subscriber to View this Content
SPONSORED CONTENT
Across healthcare, AI deployment has become a dominant conversation — yet many organizations are still overlooking one of the most important and operationally complex opportunities: pharmacy. For health system–owned pharmacies and 340B programs,
…
Provider and drug manufacturer groups are continuing to schedule high-stakes meetings with White House officials in an effort to influence [...] …
Please Login or Become a Paid Subscriber to View this Content
Four drugmakers recently announced refunds to covered entities that purchased certain 340B drugs between 2023 and 2026, while another disclosed [...] …
Please Login or Become a Paid Subscriber to View this Content
Q: What is the primary problem 340B Unscripted Podcast solves?
340B stakeholders face an increasingly complex and rapidly evolving operational and regulatory environment. Covered entities (CEs)…
Read More »
Two national 340B provider groups asked a federal judge Monday for permission to join HRSA in defending the agency’s 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
340B provider advocates and attorneys warned this week that a new Trump administration proposed rule overhauling the federal grant process [...] …
Please Login or Become a Paid Subscriber to View this Content
SPONSORED CONTENT
For health systems and pharmacies participating in 340B, compliance is not optional. It is a core operational responsibility that affects audit readiness, pharmacy performance, and patient access. In a highly specialized environment shaped by regulatory scrutiny,
…